COVID-19Ministry of Health and Family WelfareHealthIndia

COVID – 19 Vaccination Update – Day 423

India’s cumulative vaccination coverage crosses 180.36 Crore. More than 17 lakh Vaccine doses administered today till 7 pm

India’s COVID-19 vaccination coverage has crossed 180.36 Crore (1,80,36,99,367) today. More than 17 lakh (17,11,867Vaccine Doses have been administered till 7 pm today. More than 2.12 Crore (2,13,53,164) Precaution Doses for the identified categories of beneficiaries (HCWs, FLWs and Over 60 years) for COVID vaccination have been administered so far. The daily vaccination tally is expected to increase with the compilation of the final reports for the day by late tonight.

The cumulative coverage of vaccine doses, segregated based on population priority groups, is as follows:

Cumulative Vaccine Dose Coverage
HCWs 1st Dose 10402709
2nd Dose 9985772
Precaution Dose 4320934
FLWs 1st Dose 18411587
2nd Dose 17479678
Precaution Dose 6578841
Age Group 15-18 years 1st Dose 55957115
  2nd Dose 34246540
Age Group 18-44 years 1st Dose 553438905
2nd Dose 456307688
Age Group 45-59 years 1st Dose 202552380
2nd Dose 182990544
Over 60 years 1st Dose 126603319
2nd Dose 113969966
Precaution Dose 10453389
Cumulative 1st dose administered 967366015
Cumulative 2nd dose administered 814980188
Precaution Dose 21353164
Total 1803699367

 

Today’s achievement in the vaccination exercise, segregated by population priority groups, is as follows:

Date: 14th March, 2022 (423rd Day)
HCWs 1st Dose 62
2nd Dose 955
Precaution Dose 9243
FLWs 1st Dose 79
2nd Dose 1850
Precaution Dose 13520
Age Group 15-18 years 1st Dose 62662
  2nd Dose 355631
Age Group 18-44 years 1st Dose 88212
2nd Dose 792739
Age Group 45-59 years 1st Dose 13918
2nd Dose 184313
Over 60 years 1st Dose 9420
2nd Dose 116026
Precaution Dose 63237
Cumulative 1st dose administered 174353
Cumulative 2nd dose administered 1451514
Precaution Dose 86000
Total 1711867

 

The vaccination exercise as a tool to protect the most vulnerable population groups in the country from COVID-19 continues to be regularly reviewed and monitored at the highest level.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Comment moderation is enabled. Your comment may take some time to appear.

Back to top button